Nutriband Inc.

NasdaqCM NTRB

Nutriband Inc. Price to Book Ratio (P/B) on January 14, 2025: 4.25

Nutriband Inc. Price to Book Ratio (P/B) is 4.25 on January 14, 2025, a 35.62% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Nutriband Inc. 52-week high Price to Book Ratio (P/B) is 10.46 on July 24, 2024, which is 146.25% above the current Price to Book Ratio (P/B).
Nutriband Inc. 52-week low Price to Book Ratio (P/B) is 2.82 on March 14, 2024, which is -33.65% below the current Price to Book Ratio (P/B).
Nutriband Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 5.25.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: NTRB

Nutriband Inc.

CEO	Mr. Gareth Sheridan
IPO Date	Oct. 1, 2021
Location	United States
Headquarters	121 South Orange Avenue
Employees	13
Sector	Health Care
Industries Pharmaceuticals

Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Key trends

Past 5 years